Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice

被引:98
作者
Galie, M. [1 ]
Konstantinidou, G. [2 ]
Peroni, D. [1 ]
Scambi, I. [1 ]
Marchini, C. [2 ]
Lisi, V. [3 ]
Krampera, M. [3 ]
Magnani, P. [1 ]
Merigo, F. [1 ]
Montani, M. [2 ]
Boschi, F. [1 ]
Marzola, P. [1 ]
Orru, R. [2 ]
Farace, P. [1 ]
Sbarbati, A. [1 ]
Amici, A. [2 ]
机构
[1] Univ Verona, Dept Morphol & Biomed Sci, Anat & Histol Sect, I-37134 Verona, Italy
[2] Univ Camerino, Genet Immunizat Lab, Dept Mol Cellular & Anim Biol, Camerino, Macerata, Italy
[3] Univ Verona, Dept Clin & Expt Med, Haematol Sect, I-37134 Verona, Italy
关键词
mammary carcinoma; reactive stromal cells; mesenchymal stem cells; angiogenesis; molecular signature; HER-2/neu;
D O I
10.1038/sj.onc.1210920
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor microenvironment in carcinomas recruits mesenchymal cells with an abnormal proangiogenic and invasive phenotype. It is not clear whether mesenchymal tumor cells (MTCs) derive from the activation of mature fibroblasts or from their stem cell precursors. However, stromal cell activation in tumors resembles in several aspects the mesenchymal rearrangement which normally occurs during reparative processes such as wound healing. Mesenchymal stem cells (MSCs) play a crucial role in developmental and reparative processes and have extraordinary proangiogenic potential, on the basis of which they are thought to show great promise for the treatment of ischemic disorders. Here, we show that MTCs have proangiogenic potential and that they share the transcriptional expression of the best-known proangiogenic factors with MSCs. We also found that MTCs and MSCs have the same molecular signature for stemness-related genes, and that when co-implanted with cancer cells in syngeneic animals MSCs determine early tumor appearance, probably by favoring the angiogenic switch. Our data (1) reveal crucial aspects of the proangiogenic phenotype of MTCs, (2) strongly suggest their stem origin and (3) signal the risk of therapeutic use of MSCs in tumor-promoting conditions.
引用
收藏
页码:2542 / 2551
页数:10
相关论文
共 46 条
[1]   Metaplastic carcinoma of the breast Clinical presentation, treatment results and prognostic factors [J].
Al Sayed, AD ;
El Weshi, AN ;
Tulbah, AM ;
Rahal, MM ;
Ezzat, AA .
ACTA ONCOLOGICA, 2006, 45 (02) :188-195
[2]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[3]   Stromal fibroblasts in cancer initiation and progression [J].
Bhowmick, NA ;
Neilson, EG ;
Moses, HL .
NATURE, 2004, 432 (7015) :332-337
[4]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[5]   Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells [J].
Burns, JS ;
Abdallah, BM ;
Guldberg, P ;
Rygaard, J ;
Schroder, HD ;
Kassem, M .
CANCER RESEARCH, 2005, 65 (08) :3126-3135
[6]   Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo [J].
Cao, Y ;
Sun, Z ;
Liao, LM ;
Meng, Y ;
Han, Q ;
Zhao, RCH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 332 (02) :370-379
[7]   Role of tissue stroma in cancer cell invasion [J].
De Wever, O ;
Mareel, M .
JOURNAL OF PATHOLOGY, 2003, 200 (04) :429-447
[8]   Successful therapy must eradicate cancer stem cells [J].
Dingli, David ;
Michor, Franziska .
STEM CELLS, 2006, 24 (12) :2603-2610
[9]   Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts [J].
Direkze, NC ;
Hodivala-Dilke, K ;
Jeffery, R ;
Hunt, T ;
Poulsom, R ;
Oukrif, D ;
Alison, MR ;
Wright, NA .
CANCER RESEARCH, 2004, 64 (23) :8492-8495
[10]  
DVORAK HF, 1986, NEW ENGL J MED, V315, P1650